{
  "label": "clinical_signal_03_ep_025",
  "artifact_type": "signal_episode",
  "artifact_id": "sha256:85f165311cc3c9c178d95a3c28c3ecf4c8fb59d9662472a4d1b9888eb2711b4c",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:161174e8025b5c956602ccc4e17b4e677c58230b1b64641f357c400c448b8151"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T11:55:43.499119",
  "content": "## 2024-08-19 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 231\n- Active: 216\n- Screen Failures Cumulative: 42\n- Withdrawals Cumulative: 15\n\n#### Sites\n- Site 01 Enrolled: 23\n- Site 01 Active: 22\n- Site 01 Statin Concomitant: 6\n- Site 02 Enrolled: 17\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 5\n- Site 03 Enrolled: 21\n- Site 03 Active: 21\n- Site 03 Statin Concomitant: 6\n- Site 04 Enrolled: 15\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 5\n- Site 05 Enrolled: 19\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 4\n- Site 06 Enrolled: 13\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 25\n- Site 07 Active: 25\n- Site 07 Statin Concomitant: 8\n- Site 08 Enrolled: 17\n- Site 08 Active: 17\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 19\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 6\n- Site 10 Enrolled: 15\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 21\n- Site 11 Active: 20\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 17\n- Site 12 Active: 17\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n- Statin Subgroup N: 56\n- Statin Subgroup ALT (U/L) Mean: 152.0\n- Statin Subgroup ALT (U/L) Median: 150.5\n- Statin Subgroup AST (U/L) Mean: 98.1\n- Statin Subgroup AST (U/L) Median: 97.3\n- Statin Subgroup Bilirubin (mg/dL) Mean: 2.41\n- Statin Subgroup Bilirubin (mg/dL) Median: 2.41\n- Statin Subgroup ALP (U/L) Mean: 63.2\n- Statin Subgroup ALP (U/L) Median: 66.9\n- Statin Subgroup Creatinine (mg/dL) Mean: 1.09\n- Statin Subgroup Creatinine (mg/dL) Median: 0.85\n- Statin Subgroup BUN (mg/dL) Mean: 12.9\n- Statin Subgroup BUN (mg/dL) Median: 11.7\n- Statin Subgroup WBC (K) Mean: 7.5\n- Statin Subgroup WBC (K) Median: 7.2\n- Statin Subgroup Platelets (K) Mean: 241\n- Statin Subgroup Platelets (K) Median: 246\n- Non-Statin Subgroup N: 122\n- Non-Statin Subgroup ALT (U/L) Mean: 21.7\n- Non-Statin Subgroup ALT (U/L) Median: 21.0\n- Non-Statin Subgroup AST (U/L) Mean: 25.6\n- Non-Statin Subgroup AST (U/L) Median: 23.7\n- Non-Statin Subgroup Bilirubin (mg/dL) Mean: 0.89\n- Non-Statin Subgroup Bilirubin (mg/dL) Median: 0.87\n- Non-Statin Subgroup ALP (U/L) Mean: 67.1\n- Non-Statin Subgroup ALP (U/L) Median: 59.1\n- Non-Statin Subgroup Creatinine (mg/dL) Mean: 0.89\n- Non-Statin Subgroup Creatinine (mg/dL) Median: 0.96\n- Non-Statin Subgroup BUN (mg/dL) Mean: 17.3\n- Non-Statin Subgroup BUN (mg/dL) Median: 14.8\n- Non-Statin Subgroup WBC (K) Mean: 8.0\n- Non-Statin Subgroup WBC (K) Median: 6.2\n- Non-Statin Subgroup Platelets (K) Mean: 251\n- Non-Statin Subgroup Platelets (K) Median: 243\n\n### Adverse Events\n- AE ID: AE-0101, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0102, Description: back pain, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0103, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0104, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: true, Subject Group: statin\n- AE ID: AE-0105, Description: drug-induced liver injury, Grade: 3, Relatedness: definitely related, Resolved: false, Subject Group: statin\n- AE ID: AE-0106, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 28\n- Metformin Count: 22\n- PPI Count: 18\n- NSAID Count: 11\n- Other Count: 38\n\n### Protocol Deviations\n- PD ID: PD-050, Description: Eligibility criterion reassessed, subject confirmed eligible, Severity: minor, Site: site_02\n- PD ID: PD-051, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_10\n- PD ID: PD-052, Description: Missed visit window (4 days late), Severity: minor, Site: site_01\n\n### Investigator Notes\n- Query resolution rate at 94%\n- All CRFs current through prior visit cycle\n- DDI mechanism confirmed: LNS-4821 CYP3A4 inhibition leads to statin accumulation; protocol amendment drafted to exclude statin co-administration\n\n### Events\n- Site 01 new coordinator onboarding completed\n- Data management plan revision v2.5 distributed\n- CRO quarterly oversight report submitted\n- Protocol amendment v4.0 drafted; sponsor medical review initiated\n\n### Notes\n- Week 25: DDI confirmed. Protocol amendment drafted to exclude statin co-administration.",
  "metadata": {
    "episode_id": "clinical_signal_03_ep_025",
    "scope_id": "clinical_signal_03",
    "timestamp": "2024-08-19T10:00:00",
    "phase": "root_cause",
    "signal_density": "high",
    "episode_type": "signal",
    "layer_name": "signal_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "724335e48952198659b608a79f591f6985cc457d1b0726c271a193e4d218a284",
      "components": {
        "transform": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
        "inputs": "a94b84fbaca9bd62"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
      "components": {
        "transform_id": "cb4ddfa83a38701b",
        "source": "42e76241d396a578",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}